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Abstract
Background & objectives: Visceral leishmaniasis, locally known as kala-azar (KA) has been
considered as a major public health problem in Bangladesh, India and Nepal that affects 100,000
people per year with 147 million people at risk. Elimination of infectious disease is an ultimate
goal of the public health system, therefore, the efforts have recently gained momentum from various
organizations and governments to expand KA interventions in the endemic countries. The paper
aims to estimate discounted net benefits and internal rate of return (IRR) to evaluate the economic
feasibility for elimination of KA by utilizing available secondary information.
Methods: Cross-sectional data were collected from different sources to estimate societal costs of
and benefits from KA interventions with a 13-year project period. Total costs are estimated based
on the unit cost of inputs used for interventions. The benefits are derived from productivity change
and resources saved due to reduction of KA incidence. Net benefits and IRRs are estimated based
on standard procedures used in the field of economics, subsequently the sensitivity analysis is
conducted.
Results: A total discounted net benefit of KA intervention is Nepalese Rupees (NRs) 65,287 million
with 35% IRR. The result suggests that for every rupee invested in KA intervention at present will
yield NRs 71 in future. The regional benefits from the interventions will be greater than the sum of
benefits gained by the individual country due to its nature of public goods.
Conclusion: Elimination of KA is a good investment opportunity for the Government and
international partners involved in the health sector.
Key words Discount rate; internal rate of return; intervention; kala-azar; net benefits;  societal benefits; societal costs;
Nepal
Introduction
Visceral leishmaniasis, locally known as kala-azar
(KA), is one of the most neglected tropical diseases,
despite its serious consequences, if untreated, it re-
sults in a high mortality, with estimates ranging from
80 to 100%1. The disease has been considered as a
major public health problem in the Indian subconti-
nent: Bangladesh, India and Nepal that affects
100,000 people per year with 147 million people at
risk2.
Elimination of infectious disease is an ultimate goal
of the public health system, and therefore, the ef-
forts have recently gained momentum from various
organizations such as WHO/TDR, WHO-SEARO,
World Bank, UNICEF, GTZ, Bill and Melinda Gates
Foundation, Drugs for Neglected Diseases initiative
(DNDi) and the Governments of Bangladesh, India
and Nepal to eliminate KA by 2015. They have tar-
geted elimination of KA to reduce annual incidence
to less than one case per 10,000 population at the
district or subdistrict levels in the endemic countries2. J  VECTOR  BORNE  DIS  47, SEPTEMBER 2010 128
Biological and technical feasibility, political commit-
ments and economic feasibility are the primary crite-
ria for elimination of the disease3. Biological and tech-
nical feasibility mainly includes burden of disease,
improvement of case management technologies, and
preventive measures. Recently developed serologi-
cal diagnostic tools (dipstick rK39), new drugs
(miltefosine, paromomycin), personal protection
(long-lasting insecticidal nets), vector control (insec-
ticide spraying) and new evidence in transmission
cycle (no intermediate host for transmission of KA)
have confirmed the biological and technical feasibil-
ity to eliminate KA3. Sustained political and finan-
cial commitment is necessary to expand the inter-
ventions and to sustain its implementation. The health
ministers of these countries have signed a memoran-
dum of understanding on 18 May 2005 for its elimi-
nation through inter-country cooperation2. In this
particular situation, economic feasibility is the
most effective means of communicating the value of
‘elimination of KA’ and can provide powerful tool
to organize and mobilize the resources necessary
to expand the KA intervention. It provides pieces
of information about how scarce resources can be
used to derive the greatest possible net societal
benefits4.
In the literature on economic evaluation of control
or elimination of the disease, cost benefit analysis
(CBA) or cost-effectiveness analysis (CEA) are the
most popular methods that compare the costs and
consequences of an intervention to assess whether it
is worth undertaking from the economic perspective.
CBA is most appropriate among the methods of eco-
nomic evaluation for health interventions because of
its theoretical foundation in welfare economics5. CBA
is an economic tool for comparing desirables and un-
desirable impact of health interventions that suggests
in making purchasing decision6. A handful of litera-
ture is found on CBA of health interventions, and
further some studies suffer major weakness in esti-
mating the costs and benefits of the interventions5.
From an extensive search of the literature, many of
the published papers have dedicated substantial ef-
fort on CEA for disease control7–10.
The paper contributes to the aforementioned litera-
ture with comparison of the societal discounted costs
and benefits of the KA interventions in Indian sub-
continent with an example of Nepal by utilizing avail-
able secondary information. The paper aims to esti-
mate discounted net benefits and internal rate of
return (IRR) to evaluate the economic feasibility of
KA interventions. The study has particular relevance
in support of current interventions throughout south
Asian countries, which are designed for elimination
of KA. The results demonstrate quite strongly that
KA is an appropriate target for an elimination inter-
vention.
Methods
Research design: The study has used descriptive and
comparative economic evaluation design. Cross-sec-
tional data were collected from different sources and
triangulated to estimate societal costs of and ben-
efits from KA interventions with a 13-year project
horizon: 2003 through 2015.
Conceptual framework: The health production func-
tion is conceived of as having the following sequence:
inputs process  consequences (outputs/out-
comes) for an intervention of KA control. The health
production function shows a technical relation be-
tween inputs and outputs. KA related health pro-
grammes including treatment procedures, guidelines,
rules and regulations facilitate in the health produc-
tion process and ensure the technical relationships
between health inputs and outputs. We assume that
the curative and preventive interventions are con-
currently implemented to control KA.
Costs are values of resources or inputs used to pro-
duce a set of health care services to control KA. The
resources used in KA interventions are personnel,
equipments, infrastructure, drugs, vehicle, building,
patients’ time, etc. The intervention has also pro-
duced undesirable impacts, for example, environmen-
tal impact of insecticide spraying, toxicity of drugs,
painful diagnostic test, that are also included as costs
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culated using the ingredients approach. Estimates for
cost inputs were obtained through reviews of pub-
lished and unpublished literature. The costing per-
spective included costs to both the provider and the
consumer. Direct cost for treatment and indirect cost
of the time taken by the consumers to seek health
care services are also included in estimating total cost
of interventions. Therefore, costs of interventions can
be broadly classified into four categories: curative,
preventive, household direct expenses and household
time loss.
The benefits of the interventions are desirable im-
pacts that include productivity gains due to cases
prevented and reduction of morbidity (disability) and
mortality, additional utility or satisfaction due to bet-
ter quality of life, costs saved on curative treatment,
poverty reduction, improvement of educational qual-
ity for children and household economies11. People
will be healthy and able to work more hours, thereby
contributing to the overall labour productivity in the
society. Similarly, costs of KA care by service pro-
viders and households can be saved after the reduc-
tion of KA incidence. We measure benefits through
two components only: productivity change and re-
sources saved. The conceptual framework for CBA
is illustrated in Fig. 1.
Study setting and incidence: In Nepal, KA is con-
fined to 12 districts of Terai belt bordering the state
of Bihar, India and about eight million people are at
Fig. 1: Conceptual framework for cost benefit analysis (CBA)
of kala-azar
Fig. 2: Incidence of KA in Nepal from 1980 to 2006
risk. KA cases were first recorded in 1980 with <1
case/10,000 population with a case fatality rate of
5.88%. Since 1980 to 2006, a total of 28,424 cases
and 582 deaths have been reported from this dis-
ease12. In Nepal, reported incidence rates have var-
ied from about 4–5 cases/10,000 population since
2000 (Fig. 2).
Existing policy for KA intervention: KA interven-
tion aims at reducing KA morbidity and preventing
mortality by applying the primary health care ap-
proach, including active community participation.
The hospitals of endemic districts are using rK39
dipstick for diagnosis of KA. Sodium antimony glu-
conate (SAG) is the first line drug for treatment. The
second line drug is amphotericin B. New oral drug, J  VECTOR  BORNE  DIS  47, SEPTEMBER 2010 130
miltefosine that is easy to administer at the commu-
nity-level has recently been introduced. In the pre-
ventive side, indoor residual spraying (IRS) in two
cycles in a year is used for vector control. Diagnos-
tic and treatment services are provided free of cost
at public hospitals. KA elimination intervention is a
regional collaborative partnership among Nepal,
India and Bangladesh. The common consensus
has been built to apply oral drugs (miltefosine)
and rK39 diagnostic tools for the elimination
program12,13.
Strategies of KA elimination in Nepal
 Early diagnosis, prompt and complete treat-
ment of KA cases through strengthening of
referral system at the peripheral health insti-
tutions
 Early detection and timely containment of KA
epidemics
 Establishment of appropriate laboratory di-
agnostic facilities
 Protection of at-risk population (highly selec-
tive) with IRS
 Promotion of health education for commu-
nity awareness of KA, so that early diagnosis
is made and timely treatment is given
 Regular supply of drugs and logistic
 Capacity building of health personnel on KA
control and management
 Conducting field research on the epidemiol-
ogy of KA, vector bionomics and the effec-
tiveness of different anti-KA drugs
Cost estimation: Costs of interventions are the val-
ues of inputs used to control KA for a year. The in-
formation was used to plan maximum intervention
coverage with the resources available. The costs of
interventions were estimated from societal perspec-
tives. Cost of curative services includes salary, al-
lowances, first line and second line treatment (SAG
or amphotericin B), equipments, capital costs, utili-
ties, maintenance, administrative cost, training, di-
agnostic cost, and others.  Post-kala-azar dermal
leishmaniasis (PKDL) cases have not been found yet
in Nepal. Therefore, consequences of PKDL are not
included in the cost of case management. Unit cost
of per KA case management for recovery was esti-
mated through step down method. This unit cost in-
cludes cost of inpatient and outpatient services. A
KA patient in Nepal requires Nepalese Rupees (NRs)
31,223 on an average to obtain curative services from
the hospital14.
The expenses involved for preventive services are
salaries, per diem expenses for field work, vehicle
repairs and depreciation, fuel, insecticides, spraying
equipments, maps and stationery goods, monitoring
and supervision, training, etc. Some other costs are
incurred during the spraying campaigns, for example,
time and help of the house owner, possible damage
to food and furniture, etc. Unit cost of IRS was esti-
mated using ingredient method. The unit cost of IRS
per household for one time spraying is NRs 85.11
that include recurrent and capital costs15.
KA treatment and diagnosis services are provided
free of cost to the patients. However, the patients
have to pay for obtaining services like transporta-
tion, food, and associated medical cost. These costs
are direct cost of treatment. Regarding the distribu-
tion of the total direct cost of an episode of KA treat-
ment: medical costs constitute the largest share at
66.5%, followed by food, travel and other costs, at
22.6, 8.9 and 1.9%, respectively. The average total
direct cost of KA treatment is NRs 707610. The op-
portunity costs of the household, the workdays lost
(which comprised the total hospitalized days, bed rest
at home during symptomatic periods, and recovery
time) were multiplied by the prevailing market wage
rates for conversion into monetary terms. The aver-
age total opportunity cost for the household is thus,
NRs 11,00010.
Cases of KA with intervention are based on actual
reported data12 for 2003 to 2006 and estimated for
2007 to 2015; we assumed that in the interventions,
KA cases would reduce linearly to reach one case
per 10,000 population by 2015. Estimation of KA
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adjusted with existing population growth rate of en-
demic districts16. Available information suggested
that IRS covers 15% of total risk population of the
endemic districts12.
The sum of costs of all inputs gives the total cost of
the interventions, as illustrated in the conceptual
framework. By utilizing the information mentioned
above, total number of served individuals in a year
multiplied by the unit cost of the services provides
total cost of each component of the interventions.
Following formula is employed to estimate the total
cost of KA interventions:
TC = (1 +2 + 3) Y+ 4 X
Where, TC = Total cost; 1 = Unit cost of KA case
management; 2 = Average direct cost of treatment;
3 = Average indirect (resource) cost of treatment;
4 = Unit cost of IRS;  X = IRS covered population;
Y = Total KA cases in a year.
Benefit estimation: The interventions support to in-
crease KA case prevented and to reduce the morbid-
ity (disability) and mortality. This consequently in-
creases the labour availability in KA endemic districts.
The formula for the number of cases of KA prevented
for a given year is calculated as follows:
Cases of  KA prevented = (Cases of KA without
interventions – Cases of KA with  interventions)
Method of estimation of KA cases with intervention
has already been mentioned in the earlier section,
however, the estimation of KA cases without inter-
vention is determined by many factors, for example,
vector density, densities of Phlebotomus argentipes
(Diptera: Psychodidae), disease transmission, popu-
lation growth rate, existing effectiveness of IRS, cur-
rent incidence rate, climate and environmental fac-
tors, household behaviour among others. The
incidence of KA without interventions can be esti-
mated, as a rule of thumb, by utilizing the effective-
ness of IRS and reported KA cases, however, re-
ported data are grossly under reported. For example,
estimated annual incidence of KA per 10,000 popu-
lation with adjustment of under reported cases was
9 (where reported cases are 4 or 5/10,000) for Nepal
and average annual incidence for all three countries
is 22.317. In Bihar, average incidence of KA cases
was 5.7 per 1000 population based on reported data
and overall magnitude of unreported KA cases was
higher by the factor 4.1718. Similarly, the recent data
suggest that KA infection prevalence rate is 9% with
a range of 5 to 15% in Nepal19. In addition, some of
KA patients of Nepal are found to have consulted
health facilities in India for treatment. Again, if there
is no intervention, new foci of KA will arise. Sandfly
feeding behaviour results in increased transmission
rate20.  IRS has covered 15% of risk population and
its average effectiveness is only 21% in Nepal, based
on reported data21. The odds ratio of houses not
sprayed with DDT in the past six months with refer-
ence to sprayed households is 3.4 in India22; how-
ever, such information is not available in Nepal. Dur-
ing the 1960s and 1970s KA ceased to be a public
health problem which was mainly attributed to coun-
trywide malaria eradication activities with insecticide
spraying. As per existing national IRS policy, only
those villages have been sprayed, where KA cases
were recorded in the previous year. Hence, with ob-
servations of available epidemiological data of KA
and past experiences, we assume that in the absence
of KA interventions, average incidence rate of KA
would be 20: 1000 per year during project horizon
2003 to 2015.
In the absence of KA interventions, the effective
labour force (economically active population as sug-
gested by population monograph16) in the KA en-
demic areas can be broken down into infected and
non-infected individuals in the given year, similar to
that in other literatures23–24. The effective labour
force (E) in the KA endemic areas E = (l – z) L + z
(1–k) L, where (l – z) L is the labour supply of non-
infected workers and z (1–k) L is the labour supply
of infected workers. z is the proportion of  labour
force (L) that is infected in the given year. k is frac-
tion of work year lost per KA-stricken workers rang-
ing a value between 0 and 1. J  VECTOR  BORNE  DIS  47, SEPTEMBER 2010 132
In the presence of KA intervention, the effective
labour force (Ec) can similarly written as Ec = (1–zc)
L + zc (1–k)L, where zc is the fraction of labour force
infected with KA in the given year. With KA inter-
vention, zc is progressively lower than z. The incre-
mental labour input available as a result of KA inter-
vention is given by (Ec–E)  or k (z–zc) L, where (z–zc)
L is simply the number of KA cases prevented due to
KA interventions in the productive segment of the
population. Therefore, k (z–zc) L gives us the addi-
tional productive labour input available as a result of
reducing incidence of KA. Note that KA is a fatal
disease, therefore, k can be assigned a value of 1.
The percentage change in labour force as a result of
reducing incidence of KA multiplied by labour elas-
ticity gives the proportionate change in value added
due to labour effect of the interventions11. Again,
number of cases prevented due to the interventions
and unit costs gives an estimate of the amount of
money needed to allocate for curative services, thus,
direct and indirect costs of households that will be
saved.
For the estimation of benefit gains, the following for-
mula has been used:
TB = 
Where TB = Total benefits,  Proportionate change
in labour force as a result of reduced incidence of
KA;  Elasticity of labour with respect to output
for Nepal25 (using Cobb Douglas production tech-
nology) suggests that a 1% increase in the number
of workers will increase output by 0.54%; = Per
capita income from household survey (Nepal living
standard survey26) data of the endemic districts for
2003. Real gross domestic product (GDP) per capita
income that has increased by 1.6% per year27 is used
for estimation of per capita income for 2004 to 2015;
 Total cost saving due to KA cases prevented.

Where, Total KA cases prevented.
Total population at risk, effective labour force and
per capita income of the districts are given in Table 1.
All required data from different sources are entered
into the Microsoft Excel and costs and consequences
of interventions are estimated based on standard pro-
cedures used in the field of economics, subsequently
the sensitivity analysis is conducted. In turn, we esti-
mated the net present value (NPV) by utilizing so-
cial rate of discount using standard formula28.
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Where, t indicates project horizon; Bt represents to-
tal societal benefits; Ct is total societal costs.  V is
equal to NPV and r is social discount rate (10%).  If
Table 1. Population, effective labour force and per capita income of KA endemic districts for 2003
KA endemic Effective labour Total population Population Per capita
districts  force at risk growth rate income (NRs)
Jhapa 400479 688109 0.015 17377
Morang 490754 843220 0.022 15540
Sunsari 364118 625633 0.030 11897
Saptari 331904 570282 0.020 13550
Siraha 333136 572399 0.022 15049
Udayapur 167435 287689 0.026 19299
Dhanusha 390734 671364 0.021 15007
Mahottari 322126 553481 0.023 16728
Sarlahi 369978 635701 0.026 17745
Rautahat 317267 545132 0.028 16346
Bara 325417 559135 0.030 12108
Parsa 289381 497219 0.029 12285 133 ADHIKARI & SUPAKANKUNTI : COST BENEFIT ANALYSIS OF KALA-AZAR
NPV is greater than zero that ensures economic fea-
sibility to eliminate KA and if it is less than zero, KA
is not the potential candidate for elimination. By set-
ting V at zero, then estimating r by interactions, r
gives an estimate equal to IRR.
Results
Effects of interventions: Table 2 exhibits the num-
ber of cases prevented due to interventions of KA in
a year. Total cases with intervention for 2003 to 2006
were based on reported data. The result demonstrates
that not more than 316 cases should occur in Nepal
to meet the target of elimination of KA by 2015.
Costs of interventions: Preventive intervention and
curative intervention share 50 and 31% cost out of
discounted total societal cost respectively (Fig. 3).
The public sector alone has contributed 81% of total
cost (NRs 749 million). The households have con-
tributed in terms of direct and indirect costs of ob-
taining services of KA by 19%. The share of indirect
cost or opportunity cost is higher than the direct cost
because KA care is provided free of cost at the pub-
lic hospitals.
Figure 4 illustrated that all cost curves have negative
slope meaning that additional cost of each component
of interventions is going down over the year, how-
ever, the curve of curative cost is steeper than others.
In the initial year, the curative cost is higher than pre-
ventive cost. Additional preventive discounted cost
will be reduced only by 57% but additional discounted
curative cost will be reduced by >90% in the end of
project period. At least NRs 28 million discounted
costs per year will be needed to maintain the incidence
rate of KA below 1:10,000 after 2015.
Benefits from interventions: The benefits from the
KA interventions are categorized into three compo-
nents: productivity gains, saving of service obtain-
Table 2. Total KA cases prevented during the project time
Year IRS covered Total prevented Cases with Total cases without
population  cases interventions interventions
2003 1115261 91374 2222 93596
2004 1141723 92981 1889 94869
2005 1173780 94987 1605 96593
2006 1201622 97473 1365 98838
2007 1230144 99714 1160 100874
2008 1259366 102016 986 103001
2009 1289303 104377 838 105215
2010 1319974 106800 712 107512
2011 1351397 109285 605 109890
2012 1383592 111832 515 112347
2013 1416578 114444 437 114882
2014 1450375 117122 372 117493
2015 1485003 120161 316 120477
Fig. 3: Cost components of interventions in million NRs J  VECTOR  BORNE  DIS  47, SEPTEMBER 2010 134
ing cost borne by the household and saving of cura-
tive cost subsidized by the government (Fig. 5). The
diagram reveals that the society gains additional pro-
duction in term of money due to reduction of KA
that is 40% out of total discounted benefits. The
government will save a large amount of money (NRs
24,812 million) that is 37% of total discounted
benefits.
The results show that additional benefits through cost
saving will be declining throughout the project pe-
riod (Fig. 6). Additional discounted benefit from the
productivity change will be increasing over the years.
Benefit-cost analysis: The summary results in Table
3 exhibit that the mean of discounted net benefits is
around NRs 5022 million or USD 67.18 million (NRs
74.75: USD 1 for 2003). The standard deviations
suggest the risks about the cost and benefits. The
results show that obtaining discounted benefits are
at more risk than the discounted costs for interven-
tions. Total discounted net benefit is quite high, NRs
65,286 million with 35% IRR. The ratio of discounted
benefits and costs is 71:1. This means that if we in-
vest one Rupee in interventions of KA will yield NRs
71 in reference period.
Sensitivity analysis: Sensitivity analysis helps to build
confidence in the model by accommodating for the
uncertainties that are often associated with param-
eters. The analysis encompasses several techniques29.
Fig. 4: Discounted cost curves
Fig. 5: Benefit components of interventions in million NRs Fig. 6: Discounted benefit curves 135 ADHIKARI & SUPAKANKUNTI : COST BENEFIT ANALYSIS OF KALA-AZAR
Sensitivity analysis is used to identify the range of
plausible estimates for the economic consequences of
the KA epidemic and change in parameters. We used
the practical methods of handling uncertainty by us-
ing point estimates for each parameter, and conduct-
ing a sensitivity analysis by varying these estimates to
test the robustness of the conclusions of the analysis.
We take the form of a max-min analysis where all
variables are given their extreme “optimistic” and
“pessimistic” values to elicit a best and worst case
scenario. The ranges of values of the parameters with
some descriptions are presented in Table 4.
The usefulness of CBA depends largely on address-
ing the presence of uncertainty in the analysis. The
sensitivity analysis suggests the wide variation of
costs and benefits of KA interventions when the pa-
rameters have different values. Under these circum-
stances as described in Table 4, both IRRs and
societal net benefits (at 10% discount rate) are
largely fluctuated, however, total societal costs are
loosely stable (Fig. 7). The effectiveness of the in-
terventions determines the amount of societal ben-
efits. The results suggest that IRRs and discounted
net societal benefits vary from 29 to 43% and NRs
29,967 to 164,712 millions respectively (Figs. 7 and
8). Obviously, if we increase (or decrease) the so-
cial discount rate, societal net benefits will decrease
(or increase) linearly, therefore, that is not shown
in the diagram.
Table 3. Summary results of costs and benefits of KA intervention (in million NRs)
Summary results Discounted Discounted Discounted net
costs benefits benefits
Mean 72.09 5094.13 5022.04
Standard error 11.40 129.26 117.94
Median 60.45 4943.17 4882.71
Standard deviation 41.09 466.06 425.25
Sample variance 1688.21 217211.86 180841.02
Kurtosis 0.44 –0.31 –0.36
Skewness 0.99 0.89 0.88
Range 136.34 1406.70 1273.66
Minimum 27.88 4640.60 4609.42
Maximum 164.22 6047.30 5883.08
Sum 937.11 66223.69 65286.57
Fig. 7: Discounted benefits from sensitivity analysis (in
million NRs) Fig. 8: IRRs from sensitivity analysis (in %) J  VECTOR  BORNE  DIS  47, SEPTEMBER 2010 136
Table 4. Sensitivity analysis for discounted costs and benefits
Parameters Range of values Descriptions of optimistic and pessimistic
values of the parameters
Unit cost for KA 10% increase to 25% decrease Prices of resources, for example salary of health profes-
case management sional will increase over the time, therefore, it is assumed
that of the health expenditure has been increased by 10%
each year. However, introducing new drugs, such as
miltefosine and diagnostic tools are likely to  reduce cura-
tive cost and length of stay in the hospitals, hence unit
cost of care will be reduced  by about 25%.
Average direct 10% increase to 10% decrease Costs of medicine, transportation, food and accommoda-
costs of households tion are generally increasing over the years. Neverthe-
less, the improvement of access to KA care services can
reduce the direct cost of treatment.
Average indirect costs 10% increase to 10% decrease Opportunity cost is increasing with increasing per capita
of  households income and socioeconomic development in the society.
However, due to the improvement in KA case manage-
ment and access to services, loss of time can be reduced
in future.
Unit cost of IRS 10% increase to 15% decrease Cost of IRS will increase due to the increase in  cost  of
per person capital, wage rate of staff, and among others. The costs
will be decreased by 15% due to increasing awareness of
the interventions, spillover effects of the interventions,
self-motivation to control diseases among others.
Effectiveness of IRS 1 to 21% The secondary source of information suggested that the
effectiveness of IRS varies from 1 to 21%.
Elasticity of output 10% increase to 10% decrease KA disproportionately falls into rural areas where agri-
with respect to labour culture is the primary occupation of people. The labour
elasticity can be increased through improvement in agri-
culture production and agribusiness, but it can be reduced
due to disguised unemployment in the agriculture sec-
tor.
Change in per 3.4% increase to 2% decrease We have used two extreme values (the highest  and  the
capita income lowest growth rates) of real GDP per capita income in
the last decade.
Unemployment rate 2.9% to fully unemployed National unemployment rate is 2.9 and  in  the  extreme
(additional labour) case, additional labour due to KA case prevented will be
fully unemployed.
Discussion
Prior to discussing the above results, we must high-
light the study limitations. Firstly, not all costs and
benefits can be estimated in terms of market prices
and not all epidemiological data are available, and in
such cases indirect simulation methods are used in
which the treatment becomes somewhat arbitrary.
Therefore, the value judgements are inevitable. Sec-
ondly, in a study of this type that involves synthesiz-
ing data from a number of secondary sources into an
analytical framework, the parameters are subject to
uncertainty in their estimated values. For example,
unit costs may not vary at the individual patient level;
but that may vary among different treatment centres.
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modelling process because we do not know the func-
tional relationships between all parameters used in
the model. For example, what will be the relation-
ship between elasticity of labour and opportunity of
cost of treatment of the patient? Thirdly, the exter-
nalities of costs (disease) and consequences of inter-
ventions will not be limited within the project period
and within 12 endemic districts of Nepal. Therefore,
this analysis provides a truncated view of the real
implementation of the interventions. In spite of all
the limitations and pitfalls associated with epidemi-
ology, cost and consequences of the interventions,
the process is still a more reasonable procedure for
estimating net benefits and IRRs.
The economic evaluation of the health interventions
with limited information is a challenging task. Al-
most 60% of CBA related studies, therefore, were
found without estimating the benefits in monetary
terms5,30. The paper has contributed in the literature
in providing the methods of estimation with separate
components of discounted societal costs and ben-
efits of the KA intervention.
This paper has attempted to assess the economic
evaluation of KA interventions by utilizing various
sources of information. Despite the given assump-
tions and the exclusion of non-quantifiable benefits,
KA is potential candidate for elimination, however,
IRR for KA intervention is lower than chagas dis-
ease control28, but almost similar to dracunculiasis
eradication campaign24. Bassombrio et al28 estimated
benefits from the chagas disease control for a hun-
dred years and ignored the opportunity cost of house-
holds, however, we have estimated benefits for a 13-
years project duration including opportunity costs
of households and with details of cost and benefit
components. The sensitivity analysis shows that the
intervention remains highly profitable. The discounted
societal costs for interventions are more stable than
the benefits. Thus, the successful implementation of
the interventions is most important for producing
higher benefits to the society. There is a growing
consensus among concerned agencies and policy
makers that new supporting institutions and policies
are needed in order for endemic countries to capture
the full benefits of health interventions and minimize
the associated risks4. The argument for investment
gets better when other economic benefits such as
poverty reduction, improving economic welfare, and
better household economy from the KA interventions,
not reflected in natural units such as incidence, preva-
lence, disability adjusted life years (DALYs) are taken
into account. Further, the results show a consider-
able amount of money required in maintaining the
level of elimination, therefore, it requires CEA to
reset the targeted incidence of elimination of KA in
each district and to design the policy for getting more
benefits within the given level of costs.
The elimination of KA is technically and politically
feasible3, nevertheless, they have merely power to
mobilize the resources for intervention. Political com-
mitment can help to mobilize the resources through
collective action; however, there is lack of self-mo-
tivation. The economic evaluation serves as a strong
motivator for mobilizing and generating the resources
for interventions through self-motivation from local
to central or regional levels, but without economic
analysis, it is more difficult to expand the interven-
tions for elimination of KA through development of
a national agenda because KA is confined to certain
areas of the country.
Multicentre studies in Indian subcontinent17 have
suggested similar strategies for elimination of KA
for these countries. The financing and resource mo-
bilizing strategies must be similar because “elimina-
tion of KA” is a joint product of these countries.
Hence, the evidences produced in this paper will be
useful to them for developing the financing strate-
gies. “Elimination of KA” is a regional public good
that has spillover effects, for example, Bhutan or non-
KA endemic areas of the countries will get the ben-
efits from the consequences of the interventions. The
regional benefits from KA interventions, hence, will
be greater than sum of benefits gained from the indi-
vidual countries. On the other hand, the intervention
is directly related to equity of health care financing
because KA is a disease of the poor and benefits J  VECTOR  BORNE  DIS  47, SEPTEMBER 2010 138
disproportionately contribute in favour of the poor
people10.
Conclusions
This paper has developed a framework for analyzing
costs and economic consequences of KA by com-
paring with and without health interventions.  Elimi-
nation of KA is a good investment opportunity or
highly profitable investment for the governments and
international partners who want to invest in health
sector. The benefits from the interventions of KA
are not limited to endemic countries, other countries
will also benefit by keeping away from the future
risk of KA. The produced evidences in this paper
will be useful for policy makers, not only for Nepal,
but also to its neighbour countries. The KA inter-
ventions are pro-poor financing because poor people
will get greater benefits from this intervention. CBA
may serve as a strong motivator to expand the inter-
ventions because the society can easily understand
the consequences of a disease in tangible monetary
term rather than in natural units such as incidence,
prevalence, or DALYs of the disease.
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